Kemp Dolliver
Stock Analyst at Brookline Capital
(0.60)
# 4,185
Out of 5,242 analysts
19
Total ratings
38.46%
Success rate
-17.65%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LSTA Lisata Therapeutics | Downgrades: Hold | n/a | $3.18 | - | 2 | Jan 21, 2026 | |
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $0.9696 | - | 2 | Jan 21, 2026 | |
| VRCA Verrica Pharmaceuticals | Upgrades: Buy | $17 | $6.02 | +182.39% | 3 | Dec 18, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.58 | +293.01% | 1 | Jul 21, 2025 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $1.70 | +111.76% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.33 | +1,445.06% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $0.273 | +11,401.83% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $96.09 | +4.07% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $10.93 | +421.50% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.93 | +753.24% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.13 | +205.87% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.6678 | +1,097.96% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.2355 | +2,299.15% | 1 | Feb 2, 2022 |
Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $3.18
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $0.9696
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $6.02
Upside: +182.39%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.58
Upside: +293.01%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.70
Upside: +111.76%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.33
Upside: +1,445.06%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.273
Upside: +11,401.83%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $96.09
Upside: +4.07%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $10.93
Upside: +421.50%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.93
Upside: +753.24%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.13
Upside: +205.87%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.6678
Upside: +1,097.96%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.2355
Upside: +2,299.15%